{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:07:47Z","timestamp":1784686067413,"version":"3.55.0"},"publisher-location":"Singapore","reference-count":167,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_11","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"285-312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Covalent Antiviral Agents"],"prefix":"10.1007","author":[{"given":"Sako","family":"Mirzaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"GhavamiNejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.antiviral.2016.12.017","volume":"139","author":"M De Wispelaere","year":"2017","unstructured":"De Wispelaere M, Carocci M, Liang Y et al (2017) Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res 139:171\u2013179","journal-title":"Antiviral Res"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-41199-1","volume-title":"Arrestins-pharmacology and therapeutic potential","author":"EV Gurevich","year":"2014","unstructured":"Gurevich EV, Gurevich VV (2014) Therapeutic potential of small molecules and engineered proteins. In: Arrestins-pharmacology and therapeutic potential. Springer, Cham, pp 1\u201312"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","volume":"20","author":"RA Bauer","year":"2015","unstructured":"Bauer RA (2015) Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today 20:1061\u20131073","journal-title":"Drug Discov Today"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/1087057109336751","volume":"14","author":"B-F Krippendorff","year":"2009","unstructured":"Krippendorff B-F, Neuhaus R, Lienau P et al (2009) Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values. J Biomol Screen 14:913\u2013923","journal-title":"J Biomol Screen"},{"key":"11_CR5","first-page":"413","volume-title":"Annual reports in medicinal chemistry","author":"MC Noe","year":"2012","unstructured":"Noe MC, Gilbert AM (2012) Targeted covalent enzyme inhibitors. In: Annual reports in medicinal chemistry. Elsevier, Amsterdam, pp 413\u2013439"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1021\/jm8008597","volume":"52","author":"MH Potashman","year":"2009","unstructured":"Potashman MH, Duggan ME (2009) Covalent modifiers: an orthogonal approach to drug design. J Med Chem 52:1231\u20131246","journal-title":"J Med Chem"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1021\/bi050247e","volume":"44","author":"JG Robertson","year":"2005","unstructured":"Robertson JG (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44:5561\u20135571","journal-title":"Biochemistry"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","volume":"15","author":"D Lembo","year":"2018","unstructured":"Lembo D, Donalisio M, Civra A et al (2018) Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv 15:93\u2013114","journal-title":"Expert Opin Drug Deliv"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/D0MD00154F","volume":"11","author":"F Sutanto","year":"2020","unstructured":"Sutanto F, Konstantinidou M, D\u00f6mling A (2020) Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem 11:876\u2013884","journal-title":"RSC Med Chem"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","volume":"57","author":"A Tuley","year":"2018","unstructured":"Tuley A, Fast W (2018) The taxonomy of covalent inhibitors. Biochemistry 57:3326\u20133337","journal-title":"Biochemistry"},{"key":"11_CR11","first-page":"201","volume":"61","author":"JF Morrison","year":"1988","unstructured":"Morrison JF, Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 61:201\u2013301","journal-title":"Adv Enzymol"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/cbic.200500533","volume":"7","author":"SI Al-Gharabli","year":"2006","unstructured":"Al-Gharabli SI, Shah STA, Weik S et al (2006) An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 7:1048\u20131055","journal-title":"Chembiochem"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"C Gil","year":"2020","unstructured":"Gil C, Ginex T, Maestro I et al (2020) COVID-19: drug targets and potential treatments. J Med Chem 63:12359\u201312386","journal-title":"J Med Chem"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y et al (2020) Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293","journal-title":"Nature"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/JVI.02114-07","volume":"82","author":"X Xue","year":"2008","unstructured":"Xue X, Yu H, Yang H et al (2008) Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol 82:2515\u20132527","journal-title":"J Virol"},{"key":"11_CR16","doi-asserted-by":"crossref","unstructured":"Yang H, Yang M, Ding Y et al (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A 100:13190\u201313195","DOI":"10.1073\/pnas.1835675100"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","volume":"138","author":"S De Cesco","year":"2017","unstructured":"De Cesco S, Kurian J, Dufresne C et al (2017) Covalent inhibitors design and discovery. Eur J Med Chem 138:96\u2013114","journal-title":"Eur J Med Chem"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd3410","volume":"10","author":"J Singh","year":"2011","unstructured":"Singh J, Petter RC, Baillie TA et al (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307\u2013317","journal-title":"Nat Rev Drug Discov"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1021\/jm800498e","volume":"52","author":"AJ Smith","year":"2009","unstructured":"Smith AJ, Zhang X, Leach AG et al (2009) Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J Med Chem 52:225\u2013233","journal-title":"J Med Chem"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533\u2013534","journal-title":"Lancet Infect Dis"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG et al (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473","journal-title":"Lancet"},{"key":"11_CR22","unstructured":"World Health Organization (2020) Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265\u2013269","journal-title":"Nature"},{"key":"11_CR24","doi-asserted-by":"crossref","unstructured":"Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med 382:727\u2013733","DOI":"10.1056\/NEJMoa2001017"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie N, Saville M, Hatchett R et al (2020) Developing Covid-19 vaccines at pandemic speed. N Engl J Med 382:1969\u20131973","journal-title":"N Engl J Med"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/jmv.25788","volume":"92","author":"C Zhang","year":"2020","unstructured":"Zhang C, Huang S, Zheng F et al (2020) Controversial treatments: an updated understanding of the coronavirus disease 2019. J Med Virol 92:1441\u20131448","journal-title":"J Med Virol"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.antiviral.2013.08.015","volume":"100","author":"R Hilgenfeld","year":"2013","unstructured":"Hilgenfeld R, Peiris M (2013) From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res 100:286\u2013295","journal-title":"Antiviral Res"},{"key":"11_CR28","doi-asserted-by":"crossref","unstructured":"Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 30:127377","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"C Wu","year":"2020","unstructured":"Wu C, Liu Y, Yang Y et al (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 10:766\u2013788","journal-title":"Acta Pharm Sin B"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281:4085\u20134096","journal-title":"FEBS J"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2017.02.007","volume":"141","author":"V Kumar","year":"2017","unstructured":"Kumar V, Shin JS, Shie J-J et al (2017) Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res 141:101\u2013106","journal-title":"Antiviral Res"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368:409\u2013412","journal-title":"Science"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai W, Zhang B, Jiang X-M et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368:1331\u20131335","journal-title":"Science"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand K, Ziebuhr J, Wadhwani P et al (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763\u20131767","journal-title":"Science"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"e0144865","DOI":"10.1371\/journal.pone.0144865","volume":"10","author":"B-L Ho","year":"2015","unstructured":"Ho B-L, Cheng S-C, Shi L et al (2015) Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus main protease. PLoS One 10:e0144865","journal-title":"PLoS One"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.mib.2004.06.007","volume":"7","author":"J Ziebuhr","year":"2004","unstructured":"Ziebuhr J (2004) Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 7:412\u2013419","journal-title":"Curr Opin Microbiol"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar T, Manickam M, Namasivayam V et al (2016) An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 59:6595\u20136628","journal-title":"J Med Chem"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"31257","DOI":"10.1074\/jbc.M502577200","volume":"280","author":"M-F Hsu","year":"2005","unstructured":"Hsu M-F, Kuo C-J, Chang K-T et al (2005) Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 280:31257\u201331266","journal-title":"J Biol Chem"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"I Schechter","year":"1967","unstructured":"Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157\u2013162","journal-title":"Biochem Biophys Res Commun"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/med.21475","volume":"38","author":"AA Agbowuro","year":"2018","unstructured":"Agbowuro AA, Huston WM, Gamble AB et al (2018) Proteases and protease inhibitors in infectious diseases. Med Res Rev 38:1295\u20131331","journal-title":"Med Res Rev"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","volume":"92","author":"L Zhu","year":"2011","unstructured":"Zhu L, George S, Schmidt MF et al (2011) Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res 92:204\u2013212","journal-title":"Antiviral Res"},{"key":"11_CR42","doi-asserted-by":"crossref","unstructured":"Baell J, Walters MA (2014) Chemistry: chemical con artists foil drug discovery. Nature 513:481\u2013483","DOI":"10.1038\/513481a"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","volume":"27","author":"Z Jin","year":"2020","unstructured":"Jin Z, Zhao Y, Sun Y et al (2020) Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 27:529\u2013532","journal-title":"Nat Struct Mol Biol"},{"key":"11_CR44","doi-asserted-by":"crossref","unstructured":"Ma C, Sacco MD, Hurst B et al. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30:678\u2013692","DOI":"10.1038\/s41422-020-0356-z"},{"key":"11_CR45","first-page":"19839","volume":"3","author":"A Tuiskunen B\u00e4ck","year":"2013","unstructured":"Tuiskunen B\u00e4ck A, Lundkvist \u00c5 (2013) Dengue viruses\u2013an overview. Infect Ecol Epidemiol 3:19839","journal-title":"Infect Ecol Epidemiol"},{"key":"11_CR46","unstructured":"World Health Organization.\u00a0(1997).\u00a0Dengue haemorrhagic fever : diagnosis, treatment, prevention and control, 2nd ed.\u00a0World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/41988"},{"key":"11_CR47","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0140-6736(02)11276-1","volume":"360","author":"SB Halstead","year":"2002","unstructured":"Halstead SB, Deen J (2002) The future of dengue vaccines. Lancet 360:1243\u20131245","journal-title":"Lancet"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.2147\/DDDT.S94207","volume":"9","author":"X Koh-Stenta","year":"2015","unstructured":"Koh-Stenta X, Joy J, Wang SF et al (2015) Identification of covalent active site inhibitors of dengue virus protease. Drug Des Devel Ther 9:6389","journal-title":"Drug Des Devel Ther"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.antiviral.2013.09.013","volume":"100","author":"SP Lim","year":"2013","unstructured":"Lim SP, Wang Q-Y, Noble CG et al (2013) Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100:500\u2013519","journal-title":"Antiviral Res"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2011.12.003","volume":"93","author":"SM Tomlinson","year":"2012","unstructured":"Tomlinson SM, Watowich SJ (2012) Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Antiviral Res 93:245\u2013252","journal-title":"Antiviral Res"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/AAC.00855-10","volume":"55","author":"C-C Yang","year":"2011","unstructured":"Yang C-C, Hsieh Y-C, Lee S-J et al (2011) Novel dengue virus-specific NS2B\/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother 55:229\u2013238","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1021\/jm300146f","volume":"55","author":"J Deng","year":"2012","unstructured":"Deng J, Li N, Liu H et al (2012) Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J Med Chem 55:6278\u20136293","journal-title":"J Med Chem"},{"key":"11_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.antiviral.2012.02.008","volume":"94","author":"C Nitsche","year":"2012","unstructured":"Nitsche C, Behnam MA, Steuer C et al (2012) Retro peptide-hybrids as selective inhibitors of the dengue virus NS2B-NS3 protease. Antiviral Res 94:72\u201379","journal-title":"Antiviral Res"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bmcl.2005.09.062","volume":"16","author":"Z Yin","year":"2006","unstructured":"Yin Z, Patel SJ, Wang W-L et al (2006) Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg Med Chem Lett 16:36\u201339","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR55","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1128\/JVI.06225-11","volume":"86","author":"CG Noble","year":"2012","unstructured":"Noble CG, Seh CC, Chao AT et al (2012) Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol 86:438\u2013446","journal-title":"J Virol"},{"key":"11_CR56","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1128\/jvi.65.5.2467-2475.1991","volume":"65","author":"B Falgout","year":"1991","unstructured":"Falgout B, Pethel M, Zhang Y-M et al (1991) Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 65:2467\u20132475","journal-title":"J Virol"},{"key":"11_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1110\/ps.072753207","volume":"16","author":"AE Aleshin","year":"2007","unstructured":"Aleshin AE, Shiryaev SA, Strongin AY et al (2007) Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 16:795\u2013806","journal-title":"Protein Sci"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nsmb1073","volume":"13","author":"P Erbel","year":"2006","unstructured":"Erbel P, Schiering N, D'arcy A et al (2006) Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13:372\u2013373","journal-title":"Nat Struct Mol Biol"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jmb.2008.11.026","volume":"385","author":"G Robin","year":"2009","unstructured":"Robin G, Chappell K, Stoermer MJ et al (2009) Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol 385:1568\u20131577","journal-title":"J Mol Biol"},{"key":"11_CR60","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1128\/jvi.66.3.1535-1542.1992","volume":"66","author":"A Cahour","year":"1992","unstructured":"Cahour A, Falgout B, Lai C (1992) Cleavage of the dengue virus polyprotein at the NS3\/NS4A and NS4B\/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A\/NS4B may be processed by a cellular protease. J Virol 66:1535\u20131542","journal-title":"J Virol"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"8475","DOI":"10.1128\/jvi.71.11.8475-8481.1997","volume":"71","author":"K Stadler","year":"1997","unstructured":"Stadler K, Allison SL, Schalich J et al (1997) Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71:8475\u20138481","journal-title":"J Virol"},{"key":"11_CR62","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1016\/j.bmcl.2007.06.091","volume":"17","author":"MC Myers","year":"2007","unstructured":"Myers MC, Napper AD, Motlekar N et al (2007) Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays. Bioorg Med Chem Lett 17:4761\u20134766","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","volume":"60","author":"C Nitsche","year":"2017","unstructured":"Nitsche C, Zhang L, Weigel LF et al (2017) Peptide\u2013boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology. J Med Chem 60:511\u2013516","journal-title":"J Med Chem"},{"key":"11_CR64","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1021\/acsmedchemlett.7b00008","volume":"8","author":"Y Liang","year":"2017","unstructured":"Liang Y, De Wispelaere M, Carocci M et al (2017) Structure\u2013activity relationship study of QL47: a broad-Spectrum antiviral agent. ACS Med Chem Lett 8:344\u2013349","journal-title":"ACS Med Chem Lett"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/cb4008524","volume":"9","author":"H Wu","year":"2014","unstructured":"Wu H, Wang W, Liu F et al (2014) Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol 9:1086\u20131091","journal-title":"ACS Chem Biol"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/14756366.2015.1018245","volume":"31","author":"MJ Ang","year":"2016","unstructured":"Ang MJ, Lau QY, Ng FM et al (2016) Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2\u2013P4 study. J Enzyme Inhib Med Chem 31:332\u2013339","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"33663","DOI":"10.1038\/srep33663","volume":"6","author":"YW Tan","year":"2016","unstructured":"Tan YW, Ang MJY, Lau QY et al (2016) Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. Sci Rep 6:33663","journal-title":"Sci Rep"},{"key":"11_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","volume":"26","author":"PC Mcminn","year":"2002","unstructured":"Mcminn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91\u2013107","journal-title":"FEMS Microbiol Rev"},{"key":"11_CR69","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.virol.2010.12.014","volume":"411","author":"RE Rhoades","year":"2011","unstructured":"Rhoades RE, Tabor-Godwin JM, Tsueng G et al (2011) Enterovirus infections of the central nervous system. Virology 411:288\u2013305","journal-title":"Virology"},{"key":"11_CR70","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.drudis.2010.10.008","volume":"15","author":"KX Wu","year":"2010","unstructured":"Wu KX, Ng MM-L, Chu JJ (2010) Developments towards antiviral therapies against enterovirus 71. Drug Discov Today 15:1041\u20131051","journal-title":"Drug Discov Today"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.antiviral.2012.12.005","volume":"97","author":"L Shang","year":"2013","unstructured":"Shang L, Xu M, Yin Z (2013) Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res 97:183\u2013194","journal-title":"Antiviral Res"},{"key":"11_CR72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.antiviral.2010.12.007","volume":"89","author":"H Norder","year":"2011","unstructured":"Norder H, De Palma AM, Selisko B et al (2011) Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res 89:204\u2013218","journal-title":"Antiviral Res"},{"key":"11_CR73","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1128\/JVI.02491-09","volume":"84","author":"X Lei","year":"2010","unstructured":"Lei X, Liu X, Ma Y et al (2010) The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol 84:8051\u20138061","journal-title":"J Virol"},{"key":"11_CR74","doi-asserted-by":"publisher","first-page":"e1000593","DOI":"10.1371\/journal.ppat.1000593","volume":"5","author":"K-F Weng","year":"2009","unstructured":"Weng K-F, Li M-L, Hung C-T et al (2009) Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog 5:e1000593","journal-title":"PLoS Pathog"},{"key":"11_CR75","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"K Anand","year":"2002","unstructured":"Anand K, Palm GJ, Mesters JR et al (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra \u03b1-helical domain. EMBO J 21:3213\u20133224","journal-title":"EMBO J"},{"key":"11_CR76","doi-asserted-by":"crossref","unstructured":"Matthews D, Dragovich P, Webber S et al (1999) Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 96:11000\u201311007","DOI":"10.1073\/pnas.96.20.11000"},{"key":"11_CR77","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jmb.2009.07.062","volume":"392","author":"X Tian","year":"2009","unstructured":"Tian X, Lu G, Gao F et al (2009) Structure and cleavage specificity of the chymotrypsin-like serine protease (3CLSP\/nsp4) of porcine reproductive and respiratory syndrome virus (PRRSV). J Mol Biol 392:977\u2013993","journal-title":"J Mol Biol"},{"key":"11_CR78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/JVI.01587-06","volume":"81","author":"TR Sweeney","year":"2007","unstructured":"Sweeney TR, Roqu\u00e9-Rosell N, Birtley JR et al (2007) Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the \u03b2-ribbon in proteolysis. J Virol 81:115\u2013124","journal-title":"J Virol"},{"key":"11_CR79","doi-asserted-by":"publisher","first-page":"10319","DOI":"10.1128\/JVI.00787-11","volume":"85","author":"G Lu","year":"2011","unstructured":"Lu G, Qi J, Chen Z et al (2011) Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 85:10319\u201310331","journal-title":"J Virol"},{"key":"11_CR80","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1128\/JVI.05107-11","volume":"85","author":"J Wang","year":"2011","unstructured":"Wang J, Fan T, Yao X et al (2011) Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 85:10021\u201310030","journal-title":"J Virol"},{"key":"11_CR81","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jiph.2019.11.015","volume":"13","author":"AA Rabaan","year":"2020","unstructured":"Rabaan AA, Al-Ahmed SH, Bazzi AM et al (2020) Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 13:773\u2013783","journal-title":"J Infect Public Health"},{"key":"11_CR82","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/JVI.74.4.2046-2051.2000","volume":"74","author":"AA Kolykhalov","year":"2000","unstructured":"Kolykhalov AA, Mihalik K, Feinstone SM et al (2000) Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3\u2032 nontranslated region are essential for virus replication in vivo. J Virol 74:2046\u20132051","journal-title":"J Virol"},{"key":"11_CR83","doi-asserted-by":"crossref","unstructured":"Lin C, Kwong A, Perni R (2006) Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 6:3\u201316","DOI":"10.2174\/187152606776056706"},{"key":"11_CR84","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","volume":"87","author":"J Kim","year":"1996","unstructured":"Kim J, Morgenstern K, Lin C et al (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343\u2013355","journal-title":"Cell"},{"key":"11_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00005344-199702000-00013","volume":"29","author":"SS Rebello","year":"1997","unstructured":"Rebello SS, Miller BV, Basler GC et al (1997) CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 29:240\u2013249","journal-title":"J Cardiovasc Pharmacol"},{"key":"11_CR86","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1359\/jbmr.1997.12.9.1396","volume":"12","author":"BJ Votta","year":"1997","unstructured":"Votta BJ, Levy MA, Badger A et al (1997) Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12:1396\u20131406","journal-title":"J Bone Miner Res"},{"key":"11_CR87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/095632029901000505","volume":"10","author":"M Attwood","year":"1999","unstructured":"Attwood M, Bennett J, Campbell A et al (1999) The design and synthesis of potent inhibitors of hepatitis C virus NS3\u20134A proteinase. Antivir Chem Chemother 10:259\u2013273","journal-title":"Antivir Chem Chemother"},{"key":"11_CR88","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/(SICI)1099-1387(200001)6:1<11::AID-PSC229>3.0.CO;2-#","volume":"6","author":"NJ Ede","year":"2000","unstructured":"Ede NJ, Eagle SN, Wickham G et al (2000) Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein. J Pept Sci 6:11\u201318","journal-title":"J Pept Sci"},{"key":"11_CR89","unstructured":"Tung RD, Harbeson SL, Deininger DD et al. (2001) Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Patent\u00a0US20020032175A1"},{"key":"11_CR90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0960-894X(01)81080-5","volume":"1","author":"JE Baldwin","year":"1991","unstructured":"Baldwin JE, Claridge TD, Derome AE et al (1991) 11B NMR studies of an aryl boronic acid bound to chymotrypsin and subtilisin. Bioorg Med Chem Lett 1:9\u201312","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR91","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1021\/jm00009a012","volume":"38","author":"JJ Deadman","year":"1995","unstructured":"Deadman JJ, Elgendy S, Goodwin CA et al (1995) Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem 38:1511\u20131522","journal-title":"J Med Chem"},{"key":"11_CR92","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1016\/S0960-894X(02)00682-0","volume":"12","author":"ES Priestley","year":"2002","unstructured":"Priestley ES, De Lucca I, Ghavimi B et al (2002) P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 12:3199\u20133202","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR93","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1021\/ol006284+","volume":"2","author":"ES Priestley","year":"2000","unstructured":"Priestley ES, Decicco CP (2000) 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease. Org Lett 2:3095\u20133097","journal-title":"Org Lett"},{"key":"11_CR94","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0960-894X(03)00022-2","volume":"13","author":"PW Glunz","year":"2003","unstructured":"Glunz PW, Douty BD, Decicco CP (2003) Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorg Med Chem Lett 13:785\u2013788","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR95","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1016\/S0040-4039(02)02447-4","volume":"43","author":"X Zhang","year":"2002","unstructured":"Zhang X, Schmitt AC, Decicco CP (2002) Design and synthesis of 6-amino-5-oxo-1, 2, 3, 5-tetrahydro-3-indolizinecarboxylic acids as \u03b2-sheet peptidomimetics. Tetrahedron Lett 43:9663\u20139666","journal-title":"Tetrahedron Lett"},{"key":"11_CR96","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0960-894X(03)00032-5","volume":"13","author":"X Zhang","year":"2003","unstructured":"Zhang X, Schmitt AC, Jiang W et al (2003) Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 13:1157\u20131160","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR97","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bmcl.2004.01.022","volume":"14","author":"RB Perni","year":"2004","unstructured":"Perni RB, Pitlik J, Britt SD et al (2004) Inhibitors of hepatitis C virus NS3\u00b7 4A protease 2. Warhead SAR and optimization. Bioorg Med Chem Lett 14:1441\u20131446","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR98","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","volume":"50","author":"RB Perni","year":"2006","unstructured":"Perni RB, Almquist SJ, Byrn RA et al (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50:899\u2013909","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR99","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C H\u00e9zode","year":"2009","unstructured":"H\u00e9zode C, Forestier N, Dusheiko G et al (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839\u20131850","journal-title":"N Engl J Med"},{"key":"11_CR100","doi-asserted-by":"publisher","first-page":"17508","DOI":"10.1074\/jbc.M313020200","volume":"279","author":"C Lin","year":"2004","unstructured":"Lin C, Lin K, Luong Y-P et al (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 structural analysis indicates different resistance mechanisms. J Biol Chem 279:17508\u201317514","journal-title":"J Biol Chem"},{"key":"11_CR101","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer T, Bartels D et al (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767\u20131777","journal-title":"Gastroenterology"},{"key":"11_CR102","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","volume":"50","author":"B Malcolm","year":"2006","unstructured":"Malcolm B, Liu R, Lahser F et al (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50:1013\u20131020","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR103","unstructured":"UNAIDS (2021) Fact sheet 2021. UNAIDS, Geneva.\u00a0https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf"},{"key":"11_CR104","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.drudis.2017.10.017","volume":"23","author":"L Sancineto","year":"2018","unstructured":"Sancineto L, Iraci N, Tabarrini O et al (2018) NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors. Drug Discov Today 23:260\u2013271","journal-title":"Drug Discov Today"},{"key":"11_CR105","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmb.2011.03.037","volume":"410","author":"J-L Darlix","year":"2011","unstructured":"Darlix J-L, Godet J, Ivanyi-Nagy R et al (2011) Flexible nature and specific functions of the HIV-1 nucleocapsid protein. J Mol Biol 410:565\u2013581","journal-title":"J Mol Biol"},{"key":"11_CR106","doi-asserted-by":"crossref","unstructured":"McLendon G, Hull H, Larkin K et al (1999) Metal binding to the HIV nucleocapsid peptide. J Biol Inorg Chem 4:171\u2013174","DOI":"10.1007\/s007750050301"},{"key":"11_CR107","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1021\/ic801004a","volume":"47","author":"AI Anzellotti","year":"2008","unstructured":"Anzellotti AI, Bayse CA, Farrell NP (2008) Effects of nucleobase metalation on frontier molecular orbitals: potential implications for \u03c0-stacking interactions with tryptophan. Inorg Chem 47:10425\u201310431","journal-title":"Inorg Chem"},{"key":"11_CR108","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1021\/ic051644g","volume":"45","author":"AI Anzellotti","year":"2006","unstructured":"Anzellotti AI, Sabat M, Farrell N (2006) Covalent and noncovalent interactions for [metal (dien) nucleobase] 2+ complexes with L-tryptophan derivatives: formation of palladium\u2212 tryptophan species by Nucleobase substitution under biologically relevant conditions. Inorg Chem 45:1638\u20131645","journal-title":"Inorg Chem"},{"key":"11_CR109","doi-asserted-by":"publisher","first-page":"14890","DOI":"10.1074\/jbc.275.20.14890","volume":"275","author":"V Basrur","year":"2000","unstructured":"Basrur V, Song Y, Mazur SJ et al (2000) Inactivation of HIV-1 Nucleocapsid protein P7 by Pyridinioalkanoyl Thioesters characterization of reaction products and proposed mechanism of action. J Biol Chem 275:14890\u201314897","journal-title":"J Biol Chem"},{"key":"11_CR110","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1021\/jm0492195","volume":"48","author":"LM Miller Jenkins","year":"2005","unstructured":"Miller Jenkins LM, Byrd JC, Hara T et al (2005) Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters. J Med Chem 48:2847\u20132858","journal-title":"J Med Chem"},{"key":"11_CR111","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1021\/acs.jmedchem.5b01183","volume":"58","author":"L Sancineto","year":"2015","unstructured":"Sancineto L, Mariotti A, Bagnoli L et al (2015) Design and synthesis of diselenobisbenzamides (DISeBAs) as nucleocapsid protein 7 (NCp7) inhibitors with anti-HIV activity. J Med Chem 58:9601\u20139614","journal-title":"J Med Chem"},{"key":"11_CR112","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1021\/jm9802517","volume":"42","author":"JA Turpin","year":"1999","unstructured":"Turpin JA, Song Y, Inman JK et al (1999) Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J Med Chem 42:67\u201386","journal-title":"J Med Chem"},{"key":"11_CR113","doi-asserted-by":"publisher","first-page":"6180","DOI":"10.1128\/jvi.70.9.6180-6189.1996","volume":"70","author":"JA Turpin","year":"1996","unstructured":"Turpin JA, Terpening SJ, Schaeffer CA et al (1996) Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J Virol 70:6180\u20136189","journal-title":"J Virol"},{"key":"11_CR114","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1021\/tx00046a013","volume":"8","author":"X Yu","year":"1995","unstructured":"Yu X, Hathout Y, Fenselau C et al (1995) Specific disulfide formation in the oxidation of HIV-1 zinc finger protein nucleocapsid p7. Chem Res Toxicol 8:586\u2013590","journal-title":"Chem Res Toxicol"},{"key":"11_CR115","doi-asserted-by":"publisher","first-page":"a006882","DOI":"10.1101\/cshperspect.a006882","volume":"2","author":"W-S Hu","year":"2012","unstructured":"Hu W-S, Hughes SH (2012) HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2:a006882","journal-title":"Cold Spring Harb Perspect Med"},{"key":"11_CR116","doi-asserted-by":"crossref","unstructured":"Gubernick SI, F\u00e9lix N, Lee D et al (2016) The HIV therapy market. Nat Rev Drug Discov 15:451\u2013452\u00a0","DOI":"10.1038\/nrd.2016.69"},{"key":"11_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","volume":"85","author":"M-P De B\u00e9thune","year":"2010","unstructured":"De B\u00e9thune M-P (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20132009). Antiviral Res 85:75\u201390","journal-title":"Antiviral Res"},{"key":"11_CR118","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/v6104095","volume":"6","author":"P Iyidogan","year":"2014","unstructured":"Iyidogan P, Anderson KS (2014) Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 6:4095\u20134139","journal-title":"Viruses"},{"key":"11_CR119","doi-asserted-by":"crossref","unstructured":"Chan AH, Lee W-G, Spasov KA et al (2017) Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: from design to protein crystallography. Proc Natl Acad Sci U S A 114:9725\u20139730","DOI":"10.1073\/pnas.1711463114"},{"key":"11_CR120","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1021\/jacs.8b07366","volume":"140","author":"IW Windsor","year":"2018","unstructured":"Windsor IW, Palte MJ, Lukesh Iii JC et al (2018) Sub-picomolar inhibition of HIV-1 protease with a boronic acid. J Am Chem Soc 140:14015\u201314018","journal-title":"J Am Chem Soc"},{"key":"11_CR121","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1128\/AAC.02574-15","volume":"60","author":"S Thenin-Houssier","year":"2016","unstructured":"Thenin-Houssier S, De Vera IMS, Pedro-Rosa L et al (2016) Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob Agents Chemother 60:2195\u20132208","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR122","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1126\/science.1213362","volume":"336","author":"S Herfst","year":"2012","unstructured":"Herfst S, Schrauwen EJ, Linster M et al (2012) Airborne transmission of influenza a\/H5N1 virus between ferrets. Science 336:1534\u20131541","journal-title":"Science"},{"key":"11_CR123","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature10831","volume":"486","author":"M Imai","year":"2012","unstructured":"Imai M, Watanabe T, Hatta M et al (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets. Nature 486:420\u2013428","journal-title":"Nature"},{"key":"11_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms2487","volume":"4","author":"CJ Vavricka","year":"2013","unstructured":"Vavricka CJ, Liu Y, Kiyota H et al (2013) Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat Commun 4:1\u20138","journal-title":"Nat Commun"},{"key":"11_CR125","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1003749","volume":"363","author":"E Van Der Vries","year":"2010","unstructured":"Van Der Vries E, Stelma FF, Boucher CA (2010) Emergence of a multidrug-resistant pandemic influenza a (H1N1) virus. N Engl J Med 363:1381\u20131382","journal-title":"N Engl J Med"},{"key":"11_CR126","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1126\/science.1222213","volume":"337","author":"B Jagger","year":"2012","unstructured":"Jagger B, Wise H, Kash J et al (2012) An overlapping protein-coding region in influenza a virus segment 3 modulates the host response. Science 337:199\u2013204","journal-title":"Science"},{"key":"11_CR127","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11427-010-4010-8","volume":"53","author":"Y Sun","year":"2010","unstructured":"Sun Y, Shi Y, Zhang W et al (2010) In silico characterization of the functional and structural modules of the hemagglutinin protein from the swine-origin influenza virus a (H1N1)-2009. Sci China Life Sci 53:633\u2013642","journal-title":"Sci China Life Sci"},{"key":"11_CR128","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s11434-011-4517-9","volume":"56","author":"CJ Vavricka","year":"2011","unstructured":"Vavricka CJ, Liu Y, Li Q et al (2011) Special features of the 2009 pandemic swine-origin influenza a H1N1 hemagglutinin and neuraminidase. Chin Sci Bull 56:1747\u20131752","journal-title":"Chin Sci Bull"},{"key":"11_CR129","doi-asserted-by":"crossref","unstructured":"von Itzstein M (Ed.) (2012) Influenza virus sialidase \u2013 a drug discovery target. Series: Milestones in Drug Therapy, Springer.","DOI":"10.1007\/978-3-7643-8927-7"},{"key":"11_CR130","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/bi201019n","volume":"51","author":"J Chan","year":"2012","unstructured":"Chan J, Watson JN, Lu A et al (2012) Bacterial and viral sialidases: contribution of the conserved active site glutamate to catalysis. Biochemistry 51:433\u2013441","journal-title":"Biochemistry"},{"key":"11_CR131","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1021\/bi035396g","volume":"42","author":"JN Watson","year":"2003","unstructured":"Watson JN, Dookhun V, Borgford TJ et al (2003) Mutagenesis of the conserved active-site tyrosine changes a retaining sialidase into an inverting sialidase. Biochemistry 42:12682\u201312690","journal-title":"Biochemistry"},{"key":"11_CR132","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1074\/jbc.M510677200","volume":"281","author":"AG Watts","year":"2006","unstructured":"Watts AG, Oppezzo P, Withers SG et al (2006) Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on Trypanosoma rangeli sialidase. J Biol Chem 281:4149\u20134155","journal-title":"J Biol Chem"},{"key":"11_CR133","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0008-6215(94)00133-2","volume":"263","author":"T Hagiwara","year":"1994","unstructured":"Hagiwara T, Kijima-Suda I, Ido T et al (1994) Inhibition of bacterial and viral sialidases by 3-fluoro-N-acetylneuraminic acid. Carbohydr Res 263:167\u2013172","journal-title":"Carbohydr Res"},{"key":"11_CR134","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.carres.2004.02.029","volume":"339","author":"K Ikeda","year":"2004","unstructured":"Ikeda K, Kitani S, Sato K et al (2004) 2\u03b2, 3\u03b2-Difluorosialic acid derivatives structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1. Carbohydr Res 339:1367\u20131372","journal-title":"Carbohydr Res"},{"key":"11_CR135","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1139\/v04-125","volume":"82","author":"AG Watts","year":"2004","unstructured":"Watts AG, Withers SG (2004) The synthesis of some mechanistic probes for sialic acid processing enzymes and the labeling of a sialidase from Trypanosoma rangeli. Can J Chem 82:1581\u20131588","journal-title":"Can J Chem"},{"key":"11_CR136","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.1232552","volume":"340","author":"J-H Kim","year":"2013","unstructured":"Kim J-H, Resende R, Wennekes T et al (2013) Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 340:71\u201375","journal-title":"Science"},{"key":"11_CR137","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00044-013-0822-y","volume":"23","author":"L Blake","year":"2014","unstructured":"Blake L, Soliman ME (2014) Identification of irreversible protein splicing inhibitors as potential anti-TB drugs: insight from hybrid non-covalent\/covalent docking virtual screening and molecular dynamics simulations. Med Chem Res 23:2312\u20132323","journal-title":"Med Chem Res"},{"key":"11_CR138","unstructured":"Protein Data Bank (2009) PDB current holdings breakdown. https:\/\/www.rcsb.org\/stats"},{"key":"11_CR139","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.1853201","volume":"253","author":"JU Bowie","year":"1991","unstructured":"Bowie JU, Luthy R, Eisenberg D (1991) A method to identify protein sequences that fold into a known three-dimensional structure. Science 253:164\u2013170","journal-title":"Science"},{"key":"11_CR140","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10930-017-9736-8","volume":"36","author":"L Shunmugam","year":"2017","unstructured":"Shunmugam L, Ramharack P, Soliman ME (2017) Road map for the structure-based design of selective covalent HCV NS3\/4A protease inhibitors. Protein J 36:397\u2013406","journal-title":"Protein J"},{"key":"11_CR141","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/acs.jmedchem.5b00466","volume":"58","author":"RA Ward","year":"2015","unstructured":"Ward RA, Colclough N, Challinor M et al (2015) Structure-guided design of highly selective and potent covalent inhibitors of ERK1\/2. J Med Chem 58:4790\u20134801","journal-title":"J Med Chem"},{"key":"11_CR142","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","volume":"52","author":"JJ Irwin","year":"2012","unstructured":"Irwin JJ, Sterling T, Mysinger MM et al (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757\u20131768","journal-title":"J Chem Inf Model"},{"key":"11_CR143","doi-asserted-by":"crossref","unstructured":"Xie XQ (2010) Exploiting PubChem for virtual screening. Expert Opin Drug Discov 5:1205\u20131220","DOI":"10.1517\/17460441.2010.524924"},{"key":"11_CR144","doi-asserted-by":"publisher","first-page":"W409","DOI":"10.1093\/nar\/gks378","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes DR, Camacho CJ (2012) ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res 40:W409\u2013W414","journal-title":"Nucleic Acids Res"},{"key":"11_CR145","doi-asserted-by":"crossref","unstructured":"Pence HE, Williams A (2010) ChemSpider: an online chemical information resource. J Chem Educ 87:1123\u20131124","DOI":"10.1021\/ed100697w"},{"key":"11_CR146","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, Knox C, Guo AC et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668\u2013D672","journal-title":"Nucleic Acids Res"},{"key":"11_CR147","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento AP et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40:D1100\u2013D1107","journal-title":"Nucleic Acids Res"},{"key":"11_CR148","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/17460441.2010.484460","volume":"5","author":"S Cosconati","year":"2010","unstructured":"Cosconati S, Forli S, Perryman AL et al (2010) Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discovery 5:597\u2013607","journal-title":"Expert Opin Drug Discovery"},{"key":"11_CR149","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461","journal-title":"J Comput Chem"},{"key":"11_CR150","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jcc.23136","volume":"34","author":"X Ouyang","year":"2013","unstructured":"Ouyang X, Zhou S, Su CTT et al (2013) CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. J Comput Chem 34:326\u2013336","journal-title":"J Comput Chem"},{"key":"11_CR151","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/prot.10465","volume":"52","author":"ML Verdonk","year":"2003","unstructured":"Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein\u2013ligand docking using GOLD. Proteins Struct Funct Bioinform 52:609\u2013623","journal-title":"Proteins Struct Funct Bioinform"},{"key":"11_CR152","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212 ligand complexes. J Med Chem 49:6177\u20136196","journal-title":"J Med Chem"},{"key":"11_CR153","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1021\/ci500118s","volume":"54","author":"K Zhu","year":"2014","unstructured":"Zhu K, Borrelli KW, Greenwood JR et al (2014) Docking covalent inhibitors: a parameter free approach to pose prediction and scoring. J Chem Inf Model 54:1932\u20131940","journal-title":"J Chem Inf Model"},{"key":"11_CR154","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/ci500681r","volume":"55","author":"C Scholz","year":"2015","unstructured":"Scholz C, Knorr S, Hamacher K et al (2015) Docktite a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment. J Chem Inf Model 55:398\u2013406","journal-title":"J Chem Inf Model"},{"key":"11_CR155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1761880","volume":"2020","author":"MA Alamri","year":"2020","unstructured":"Alamri MA, Tahir Ul Qamar M, Mirza MU et al (2020) Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro. J Biomol Struct Dyn 2020:1\u201313","journal-title":"J Biomol Struct Dyn"},{"key":"11_CR156","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2174\/1381612043452721","volume":"10","author":"T Hou","year":"2004","unstructured":"Hou T, Xu X (2004) Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 10:1011\u20131033","journal-title":"Curr Pharm Des"},{"key":"11_CR157","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/jmv.25357","volume":"91","author":"MU Mirza","year":"2019","unstructured":"Mirza MU, Vanmeert M, Ali A et al (2019) Perspectives towards antiviral drug discovery against Ebola virus. J Med Virol 91:2029\u20132048","journal-title":"J Med Virol"},{"key":"11_CR158","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","volume":"353","author":"T-W Lee","year":"2005","unstructured":"Lee T-W, Cherney MM, Huitema C et al (2005) Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J Mol Biol 353:1137\u20131151","journal-title":"J Mol Biol"},{"key":"11_CR159","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","volume":"150","author":"ACG Kankanamalage","year":"2018","unstructured":"Kankanamalage ACG, Kim Y, Damalanka VC et al (2018) Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem 150:334\u2013346","journal-title":"Eur J Med Chem"},{"key":"11_CR160","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T et al (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221\u2013234","journal-title":"J Comput Aided Mol Des"},{"key":"11_CR161","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","volume":"25","author":"T Pillaiyar","year":"2020","unstructured":"Pillaiyar T, Meenakshisundaram S, Manickam M (2020) Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 25:668\u2013688","journal-title":"Drug Discov Today"},{"key":"11_CR162","doi-asserted-by":"crossref","unstructured":"Tang B, He F, Liu D et al. (2020) AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2. bioRxiv [Preprint] Mar 8:2020.03.03.972133","DOI":"10.1101\/2020.03.03.972133"},{"key":"11_CR163","first-page":"1","volume":"2020","author":"M Chakravarty","year":"2020","unstructured":"Chakravarty M, Vora A (2020) Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res 2020:1\u201340","journal-title":"Drug Deliv Transl Res"},{"key":"11_CR164","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1007\/s11095-008-9615-2","volume":"25","author":"N Chattopadhyay","year":"2008","unstructured":"Chattopadhyay N, Zastre J, Wong H-L et al (2008) Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 25:2262\u20132271","journal-title":"Pharm Res"},{"key":"11_CR165","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/pharmaceutics12020171","volume":"12","author":"F-D Cojocaru","year":"2020","unstructured":"Cojocaru F-D, Botezat D, Gardikiotis I et al (2020) Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics 12:171","journal-title":"Pharmaceutics"},{"key":"11_CR166","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.addr.2009.11.020","volume":"62","author":"HL Wong","year":"2010","unstructured":"Wong HL, Chattopadhyay N, Wu XY et al (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 62:503\u2013517","journal-title":"Adv Drug Deliv Rev"},{"key":"11_CR167","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.addr.2011.10.007","volume":"64","author":"HL Wong","year":"2012","unstructured":"Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64:686\u2013700","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:37:33Z","timestamp":1699231053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":167,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_11","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}